{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:50:35Z","timestamp":1791474635894,"version":"4.3.4"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"MRFF Practitioner Fellowship"},{"name":"Moyira Elizabeth Vine Fund for Research into Schizophrenia Scheme"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>N-acetyl cysteine (NAC) is a potent antioxidant that modulates glutamatergic signalling which is thought to play a role in alcohol use disorder (AUD). There have been no clinical trials investigating NAC for AUD. We aimed to conduct a 28\u00a0day double-blind, placebo-controlled (PL) randomized trial of NAC in the treatment of AUD (NCT03879759). A total of 42 participants with AUD (56% alcohol-related liver disease) were randomized to receive placebo or NAC 2400\u00a0mg\/day. Feasibility outcomes included treatment retention and adverse events. Primary clinical outcomes included alcohol consumption (heavy drinking days, standard drinks per drinking day). Secondary clinical outcome measures included craving, liver tests, and psychological outcomes. There were no significant differences in overall retention between treatment groups (\u03c72(1)\u2009=\u20090.14, P\u00a0=\u20090.71: 86% vs 76% for placebo and NAC, respectively). The most commonly reported adverse event in NAC-treated individuals included headache (14%). For standard drinks per drinking day, there was a significant overall effect of time (F\u00a0=\u20099.18, P\u00a0&amp;lt;\u20090.001), no significant effect of treatment (F\u00a0=\u20090.75, P\u00a0=\u20090.79), and a significant time x treatment (NAC vs PL) effect (F\u00a0=\u20092.73, P\u00a0&amp;lt;\u20090.05). For number of heavy drinks per day, there was a significant overall effect of time (F\u00a0=\u20093.16, P\u00a0&amp;lt;\u20090.05) but no significant effect of treatment or time x treatment (P\u00a0=\u20090.17). There were no significant NAC vs PL effects on secondary clinical outcome measures. In the first trial of NAC for the management of AUD, NAC appears to be feasible and safe. Although there was a significant effect of NAC vs placebo on some alcohol measures such as drinks per drinking day, there does appear to be a variable pattern of effect across time suggesting that a larger trial incorporating a longer treatment duration is now required to determine efficacy.<\/jats:p>","DOI":"10.1093\/alcalc\/agad044","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T04:40:01Z","timestamp":1689741601000},"page":"553-560","source":"Crossref","is-referenced-by-count":24,"title":["N acetylcysteine in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1093","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0868-9928","authenticated-orcid":false,"given":"Kirsten C","family":"Morley","sequence":"first","affiliation":[{"name":"Specialty of Addiction Medicine, Sydney Medical School, Faculty of Medicine and Health, University of Sydney , NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siena","family":"Peruch","sequence":"additional","affiliation":[{"name":"Specialty of Addiction Medicine, Sydney Medical School, Faculty of Medicine and Health, University of Sydney , NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Adams","sequence":"additional","affiliation":[{"name":"Specialty of Addiction Medicine, Sydney Medical School, Faculty of Medicine and Health, University of Sydney , NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Towers","sequence":"additional","affiliation":[{"name":"Specialty of Addiction Medicine, Sydney Medical School, Faculty of Medicine and Health, University of Sydney , NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Tremonti","sequence":"additional","affiliation":[{"name":"Edith Collins Centre for Translational Research, Level6, KGV Buidling, Missenden Road, Sydney Local Health District, Royal Prince Alfred Hospital , NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Watt","sequence":"additional","affiliation":[{"name":"Edith Collins Centre for Translational Research, Level6, KGV Buidling, Missenden Road, Sydney Local Health District, Royal Prince Alfred Hospital , NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazila","family":"Jamshidi1","sequence":"additional","affiliation":[{"name":"Specialty of Addiction Medicine, Sydney Medical School, Faculty of Medicine and Health, University of Sydney , NSW , Australia"},{"name":"Edith Collins Centre for Translational Research, Level6, KGV Buidling, Missenden Road, Sydney Local Health District, Royal Prince Alfred Hospital , NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S","family":"Haber","sequence":"additional","affiliation":[{"name":"Specialty of Addiction Medicine, Sydney Medical School, Faculty of Medicine and Health, University of Sydney , NSW , Australia"},{"name":"Edith Collins Centre for Translational Research, Level6, KGV Buidling, Missenden Road, Sydney Local Health District, Royal Prince Alfred Hospital , NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"2023122810033930200_ref1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1476-5381.2009.00562.x","article-title":"Cue-conditioned alcohol seeking in rats following abstinence: involvement of metabotropic glutamate 5 receptors","volume":"159","author":"Adams","year":"2010","journal-title":"Br J Pharmacol"},{"key":"2023122810033930200_ref2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2215-0366(18)30303-1","article-title":"Baclofen for the treatment of alcohol use disorder: the Cagliari statement","volume":"5","author":"Agabio","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"2023122810033930200_ref3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1389-9457(00)00065-4","article-title":"Validation of the insomnia severity index as an outcome measure for insomnia research","volume":"2","author":"Bastien","year":"2001","journal-title":"Sleep Med"},{"key":"2023122810033930200_ref4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00606662","article-title":"Pharmacokinetics of N-acetylcysteine in man","volume":"31","author":"Borgstr\u00f6m","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"2023122810033930200_ref5","volume-title":"Improving Compliance with Alcoholism Treatment","author":"Carroll"},{"key":"2023122810033930200_ref6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1359-6357.2003.00581.x","article-title":"Traditional markers of excessive alcohol use","volume":"98","author":"Conigrave","year":"2003","journal-title":"Addiction"},{"key":"2023122810033930200_ref7","doi-asserted-by":"crossref","first-page":"13397","DOI":"10.1038\/s41598-021-92676-0","article-title":"The use of N-acetylcysteine in the prevention of hangover: a randomized trial","volume":"11","author":"Coppersmith","year":"2021","journal-title":"Sci Rep"},{"key":"2023122810033930200_ref8","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1530-0277.1999.tb04349.x","article-title":"Psychometric properties of the Penn alcohol craving scale","volume":"23","author":"Flannery","year":"1999","journal-title":"Alcoholism: Clinical & Experimental Research"},{"key":"2023122810033930200_ref9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4088\/JCP.13m08411","article-title":"A randomized, placebo-controlled trial of N-Acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers","volume":"75","author":"Grant","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"2023122810033930200_ref10","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamapsychiatry.2016.0060","article-title":"N-Acetylcysteine in the treatment of excoriation disorder: a randomized clinical trial","volume":"73","author":"Grant","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"2023122810033930200_ref11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.5694\/mja2.51254","article-title":"New Australian guidelines for the treatment of alcohol problems: an overview of recommendations","volume":"215","author":"Haber","year":"2021","journal-title":"Med J Aust"},{"key":"2023122810033930200_ref12","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1111\/acer.12205","article-title":"Missing data in alcohol clinical trials: a comparison of methods","volume":"37","author":"Hallgren","year":"2013","journal-title":"Alcohol Clin Exp Res"},{"key":"2023122810033930200_ref13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.12688\/f1000research.9609.1","article-title":"Glutamate plasticity woven through the progression to alcohol use disorder: a multi-circuit perspective","volume":"6","author":"Hwa","year":"2017","journal-title":"F1000Research"},{"key":"2023122810033930200_ref14","doi-asserted-by":"crossref","first-page":"e12853","DOI":"10.1111\/adb.12853","article-title":"Aspirin and N-acetylcysteine co-administration markedly inhibit chronic ethanol intake and block relapse binge drinking: role of neuroinflammation-oxidative stress self-perpetuation","volume":"26","author":"Israel","year":"2021","journal-title":"Addict Biol"},{"key":"2023122810033930200_ref15","first-page":"12","article-title":"N-acetylcysteine improves liver function in patients with non-alcoholic fatty liver disease","volume":"10","author":"Khoshbaten","year":"2010","journal-title":"Hepatitis Monthly"},{"key":"2023122810033930200_ref16","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-023-01553-z","article-title":"N-acetylcysteine does not alter neurometabolite levels in non-treatment seeking adolescents who use alcohol heavily: a preliminary randomized clinical trial","volume":"48","author":"Kirkland","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"2023122810033930200_ref17","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1007\/s00213-020-05629-2","article-title":"N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials","volume":"237","author":"Kishi","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"2023122810033930200_ref18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/adb.12521","article-title":"Effect of N-acetylcysteine on motivation, seeking and relapse to ethanol self-administration","volume":"23","author":"Lebourgeois","year":"2018","journal-title":"Addict Biol"},{"key":"2023122810033930200_ref19","volume-title":"Manual for the Depression Anxiety Stress Scales","author":"Lovibond","year":"1995"},{"key":"2023122810033930200_ref20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12916-014-0145-y","article-title":"Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis","volume":"12","author":"Mokdad","year":"2014","journal-title":"BMC Med"},{"key":"2023122810033930200_ref21","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1111\/add.15532","article-title":"Commentary on Donoghue: low prescribing rates of pharmacotherapy for alcohol use disorder limit potential public health impact","volume":"116","author":"Morley","year":"2021","journal-title":"Addiction"},{"key":"2023122810033930200_ref22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.2018.13","article-title":"Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial","volume":"212","author":"Morley","year":"2018","journal-title":"Br J Psychiatry"},{"key":"2023122810033930200_ref23","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/13543784.2018.1501471","article-title":"N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: rationale for further research [review]","volume":"27","author":"Morley","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"2023122810033930200_ref24","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/14656566.2021.1892641","article-title":"New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies","volume":"22","author":"Morley","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"2023122810033930200_ref25","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1101214","article-title":"Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis","volume":"365","author":"Nguyen-Khac","year":"2011","journal-title":"N Engl J Med"},{"key":"2023122810033930200_ref26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1179\/1351000215Y.0000000004","article-title":"N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study","volume":"20","author":"Prado","year":"2015","journal-title":"Redox Rep"},{"key":"2023122810033930200_ref27","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/acer.13031","article-title":"Beyond the \u201cfirst hit\u201d: marked inhibition by N-acetyl cysteine of chronic ethanol intake but not of early ethanol intake. Parallel effects on ethanol-induced saccharin motivation","volume":"40","author":"Quintanilla","year":"2016","journal-title":"Alcohol Clin Exp Res"},{"key":"2023122810033930200_ref28","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/acer.13842","article-title":"Commonality of ethanol and nicotine reinforcement and relapse in Wistar-derived UChB rats: inhibition by N-Acetylcysteine","volume":"42","author":"Quintanilla","year":"2018","journal-title":"Alcohol Clin Exp Res"},{"key":"2023122810033930200_ref29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/alcalc\/agr023","article-title":"Ceftriaxone, a Beta-lactam antibiotic, reduces ethanol consumption in alcohol-preferring rats","volume":"46","author":"Sari","year":"2015","journal-title":"Alcohol Alcohol"},{"key":"2023122810033930200_ref30","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s11064-017-2218-8","article-title":"N-acetylcysteine prevents alcohol related Neuroinflammation in rats","volume":"42","author":"Schneider","year":"2017","journal-title":"Neurochem Res"},{"key":"2023122810033930200_ref31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addbeh.2017.11.044","article-title":"The effect of N-acetylcysteine and working memory training on cocaine use, craving and inhibition in regular cocaine users: correspondence of lab assessments and ecological momentary assessment","volume":"79","author":"Schulte","year":"2017","journal-title":"Addict Behav"},{"key":"2023122810033930200_ref32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addbeh.2017.11.044","article-title":"The effect of N-acetylcysteine and working memory training on cocaine use, craving and inhibition in regular cocaine users: correspondence of lab assessments and ecological momentary assessment","volume":"79","author":"Schulte","year":"2018","journal-title":"Addict Behav"},{"key":"2023122810033930200_ref33","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"Br Med J"},{"key":"2023122810033930200_ref34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.alcohol.2009.09.028","article-title":"Alcoholism and alcohol abstinence: N-acetylcysteine to improve energy expenditure, myocardial oxidative stress, and energy metabolism in alcoholic heart disease","volume":"43","author":"Seiva","year":"2009","journal-title":"Alcohol"},{"key":"2023122810033930200_ref35","first-page":"22","article-title":"The Mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"2023122810033930200_ref36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1037\/0021-843X.91.3.199","article-title":"Alcohol dependence syndrome: measurement and validation","volume":"91","author":"Skinner","year":"1982","journal-title":"J Abnorm Psychol"},{"key":"2023122810033930200_ref37","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0005-7967(79)90025-1","article-title":"Reliability of alcohol abusers' self-reports of drinking behavior","volume":"17","author":"Sobell","year":"1979","journal-title":"Behav Res Ther"},{"key":"2023122810033930200_ref38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drugalcdep.2017.12.005","article-title":"The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial","volume":"185","author":"Squeglia","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"2023122810033930200_ref39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40429-018-0211-1","article-title":"Pharmacotherapy for alcohol use disorder and alcoholic liver disease","volume":"5","author":"Stocklosa","year":"2018","journal-title":"Curr Addict Rep"},{"key":"2023122810033930200_ref40","doi-asserted-by":"crossref","first-page":"173037","DOI":"10.1016\/j.pbb.2020.173037","article-title":"Influence of n-acetylcysteine maintenance on the pharmacodynamic effects of oral ethanol","volume":"198","author":"Stoops","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"2023122810033930200_ref41","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br J Addict"},{"key":"2023122810033930200_ref42","volume-title":"Global Status Report on Alcohol and Health 2018 (9241565632)","author":"World Health Organization","year":"2018"}],"container-title":["Alcohol and Alcoholism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/alcalc\/article-pdf\/58\/5\/553\/54912664\/agad044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/alcalc\/article-pdf\/58\/5\/553\/54912664\/agad044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T05:59:07Z","timestamp":1703743147000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/alcalc\/article\/58\/5\/553\/7225905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,7,18]]},"published-print":{"date-parts":[[2023,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/alcalc\/agad044","relation":{},"ISSN":["0735-0414","1464-3502"],"issn-type":[{"value":"0735-0414","type":"print"},{"value":"1464-3502","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,7,18]]}}}